OBJECTIVE:Low birth weight infants are at risk for iron deficiency (ID). Most LBW infants have marginally low birth weight (MLBW, 2000-2500 g) and it is not known whether they benefit from iron supplements. The objective of this trial was to study the effects of iron supplementation in MLBW infants. METHOD: In a randomized controlled trial, we assigned 285 healthy, MLBW infants to receiveiron supplements at a dose of 0 (placebo), 1, or 2 mg/kg per day between 6 weeks and 6 months of age. Hemoglobin levels, ferritin levels, transferrin saturation, mean cell volume, and transferrin receptor levels were analyzed at 6 months. Growth and morbidity were monitored. RESULTS:Iron supplementation resulted in significant dose-dependent effects on hemoglobin and all iron status indicators at 6 months. The prevalence of ID at 6 months was 36% in the placebo group, 8.2% in the 1 mg/kg per day group, and 3.8% in the 2 mg/kg per day group (P<.001). The prevalence rates of ID anemia (IDA) were 9.9%, 2.7%, and 0%, respectively (P=.004). Among infants who were exclusively breastfed at 6 weeks, the prevalence of IDA was 18% in the placebo group. There were no significant differences between groups in growth or morbidity. CONCLUSIONS:MLBW infants have relatively high risks of ID and IDA, especially if they are breastfed. Iron supplementation at 2 mg/kg per day from 6 weeks to 6 months reduces this risk effectively, with no short-term adverse effects on morbidity or growth.
RCT Entities:
OBJECTIVE: Low birth weight infants are at risk for iron deficiency (ID). Most LBW infants have marginally low birth weight (MLBW, 2000-2500 g) and it is not known whether they benefit from iron supplements. The objective of this trial was to study the effects of iron supplementation in MLBW infants. METHOD: In a randomized controlled trial, we assigned 285 healthy, MLBW infants to receive iron supplements at a dose of 0 (placebo), 1, or 2 mg/kg per day between 6 weeks and 6 months of age. Hemoglobin levels, ferritin levels, transferrin saturation, mean cell volume, and transferrin receptor levels were analyzed at 6 months. Growth and morbidity were monitored. RESULTS:Iron supplementation resulted in significant dose-dependent effects on hemoglobin and all iron status indicators at 6 months. The prevalence of ID at 6 months was 36% in the placebo group, 8.2% in the 1 mg/kg per day group, and 3.8% in the 2 mg/kg per day group (P<.001). The prevalence rates of ID anemia (IDA) were 9.9%, 2.7%, and 0%, respectively (P=.004). Among infants who were exclusively breastfed at 6 weeks, the prevalence of IDA was 18% in the placebo group. There were no significant differences between groups in growth or morbidity. CONCLUSIONS: MLBW infants have relatively high risks of ID and IDA, especially if they are breastfed. Iron supplementation at 2 mg/kg per day from 6 weeks to 6 months reduces this risk effectively, with no short-term adverse effects on morbidity or growth.
Authors: Staffan K Berglund; Anna Chmielewska; Josefine Starnberg; Björn Westrup; Bruno Hägglöf; Mikael Norman; Magnus Domellöf Journal: Pediatr Res Date: 2017-10-25 Impact factor: 3.756
Authors: C G de Waal; L Uijterschout; M Abbink; B Boersma; P Vos; W W Rövekamp; F Hudig; M D Akkermans; J B van Goudoever; F Brus Journal: J Perinatol Date: 2017-02-09 Impact factor: 2.521
Authors: Dominic J Hare; Manish Arora; Nicole L Jenkins; David I Finkelstein; Philip A Doble; Ashley I Bush Journal: Nat Rev Neurol Date: 2015-06-23 Impact factor: 42.937
Authors: Josefine Starnberg; Mikael Norman; Björn Westrup; Magnus Domellöf; Staffan K Berglund Journal: Pediatr Res Date: 2018-05-02 Impact factor: 3.756
Authors: L Uijterschout; M Domellöf; M Abbink; S K Berglund; I van Veen; P Vos; L Rövekamp; B Boersma; C Hudig; R Vos; J B van Goudoever; F Brus Journal: Eur J Clin Nutr Date: 2014-10-15 Impact factor: 4.016
Authors: Jo Ann D'Agostino; Molly Passarella; Philip Saynisch; Ashley E Martin; Michelle Macheras; Scott A Lorch Journal: Pediatrics Date: 2015-10 Impact factor: 7.124
Authors: M D Akkermans; L Uijterschout; M Abbink; P Vos; L Rövekamp-Abels; B Boersma; J B van Goudoever; F Brus Journal: Eur J Clin Nutr Date: 2016-03-23 Impact factor: 4.016